BSE Code: | NSE Code: | ISIN: | Sector:
Research Report Detail
|Report Date||Call||Price@Call||Target Price
|Current Status||Time Horizon|
|Target Hit|| Long (1Y)
CLSA reinitiates Cadila Healthcare with underperform
CLSA says US and India formulations are primary growth drivers. However current valuations leave limited upside potential. Strong growth prospects seem to be priced in, added CLSA.